After two U.S. acquisitions back in February, Quotient Clinical has been renamed as Quotient Sciences, and right after that, made another purchase.
U.K.-based CDMO Pharmaterials is now part of the rebranded Quotient Sciences. Quotient said in a release that the acquisition strengthens its formulation and manufacturing services footprint in its home country.
Services offered at Pharmaterials fall within Quotient’s existing portfolio, including characterization and optimization of small-molecule drug physical forms, the development of preclinical and clinical formulations, as well as contract manufacturing for clinical use and commercial supply.
Founded in 2000, Pharmaterials has established 13 GMP manufacturing suites in a 48,000-square-feet facility, which also has more space for future expansion.
Quotient entered the U.S. market through two closely announced acquisitions in February—clinical pharmacology expert Seaview and Charles River Laboratories’ CDMO unit QS Pharma.
“Quotient’s overall strategy behind the acquisitions over the last 12 months is to replicate our Translational Pharmaceutics platform in the USA,” Quotient spokesperson Robin Bodicoat told FierceCRO.
The platform works by combining services from traditional CDMOs with those from CROs, namely integrating formulation development and early-stage clinical research with GMP manufacturing. The company said the approach is proven to reduce drug development costs and shorten timelines.
After these acquisitions, Quotient now has 700 employees working at five sites in the U.S. and the U.K.
By Angus Liu
Source: Fierce Biotech
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
